trifluoperazine has been researched along with Lupus Erythematosus, Systemic in 2 studies
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tishler, M | 1 |
| Abramov, AL | 1 |
2 other studies available for trifluoperazine and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Systemic lupus erythematosus presenting as catatonic schizophrenia.
Topics: Adult; Blood Sedimentation; Humans; Lupus Erythematosus, Systemic; Prednisone; Schizophrenia, Catato | 1985 |
Drug-induced extrapyramidal symptoms. A cooperative study.
Topics: Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenones; Chlorpromazine; | 1973 |